drugset
drugset / Trial / NCT00205231

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

NCT00205231 ↗

Completed 25 enrolled University of Wisconsin, Madison Immunex Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.

Timeline

Start
2002-05
Primary completion
2004-05-01
Completion
2004-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic — —

Indications

HIV infectious disease